Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01370317 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT01370317 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 27 participants.
The verdict
NCT01370317, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of multiple dose treatment with MK-1029 in adults with mild to moderate persistent asthma.
Interventions
- DRUG MK-1029
- DRUG Placebo for MK-1029
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2011-06-01 |
| Est. Completion | 2011-12-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01370317
The ClinicalTrials.gov registry entry for NCT01370317 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MK-1029 is the first listed.
NCT01370317 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01370317 about?
NCT01370317 is a clinical study titled "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma". This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of multiple dose treatment with MK-1029 in adults with mild to moderate persistent asthma.
What is the current status of trial NCT01370317?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2011-06-01. Estimated completion is 2011-12-27.
What interventions are being tested in trial NCT01370317?
The interventions under investigation include: MK-1029 (DRUG), Placebo for MK-1029 (DRUG).
Who is sponsoring clinical trial NCT01370317?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.